Page 1 of 87
GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS
SOLVED QUESTIONS & ANSWERS VERIFIED 100 %
Goodman and Gilman's The Pharmacological Basis of Therapeutics – Questions
with Detailed Rationales
SECTION 1: GENERAL PRINCIPLES OF PHARMACOLOGY (Q1–Q25)
Q1. Which statement best describes the historical role of medicinal plants in drug
discovery?
A. They primarily provided inactive placebo compounds
B. They served as direct sources of pharmacologically active molecules
C. They were used mainly to validate synthetic drug libraries
D. They contributed only to toxicology research
Correct Answer: B
Rationale: Goodman & Gilman describes medicinal plants as foundational sources of
bioactive compounds that directly led to the discovery of many therapeutic agents.
Morphine, quinine, and digoxin are examples of plant-derived drugs that remain
clinically essential.
Q2. What is the primary goal of lead compound optimization?
, Page 2 of 87
A. Eliminate all adverse effects
B. Improve potency, selectivity, and pharmacokinetic properties
C. Reduce molecular weight below a fixed threshold
D. Ensure complete receptor antagonism
Correct Answer: B
Rationale: Lead optimization focuses on enhancing efficacy, selectivity, and drug-like
properties while minimizing toxicity, as described in the drug discovery process.
Q3. A pharmaceutical team identifies a potent alkaloid from a medicinal plant that
inhibits a CNS enzyme but has poor oral bioavailability and high polar surface area.
Which lead-optimization strategy most directly addresses oral absorption and
brain exposure while preserving the core scaffold?
A. Introduce a permanently charged tertiary amine to increase water solubility
B. Mask polar groups as bioreversible esters (prodrug approach) to improve
permeability
C. Add multiple polar hydroxyl groups to enhance hydrogen bonding with plasma
proteins
D. Increase molecular weight by appending bulky aromatic rings to reduce clearance
Correct Answer: B
Rationale: Masking polar groups as bioreversible esters (a prodrug strategy) transiently
reduces polar surface area and increases membrane permeability for oral absorption
and CNS entry; esterase-mediated conversion regenerates the active scaffold.
Q4. High-throughput screening (HTS) is best described as:
A. Manual testing of compounds in animal models
B. Computational prediction of drug-receptor binding
C. Automated testing of large compound libraries against biological targets
D. Post-marketing surveillance of adverse drug reactions
, Page 3 of 87
Correct Answer: C
Rationale: HTS is defined as an automated method allowing rapid evaluation of
thousands of compounds for biological activity against specific targets.
Q5. Which term refers to a compound that shows desirable biological activity but
requires modification before clinical use?
A. Prodrug
B. Lead compound
C. Biomarker
D. Excipient
Correct Answer: B
Rationale: A lead compound is identified during screening as having promising activity
and serves as the starting point for further chemical refinement.
Q6. What is the primary determinant of a drug's ability to cross the blood-brain
barrier?
A. Molecular weight only
B. Lipophilicity and polar surface area
C. Plasma protein binding only
D. Route of administration only
Correct Answer: B
Rationale: The ability to cross the blood-brain barrier depends primarily on lipophilicity
(logP) and polar surface area (PSA). Drugs with high lipophilicity and low PSA penetrate
the CNS more readily.
Q7. Which pharmacokinetic parameter determines the loading dose required to
achieve a target plasma concentration?
, Page 4 of 87
A. Clearance
B. Volume of distribution (Vd)
C. Elimination half-life
D. Bioavailability only
Correct Answer: B
Rationale: The loading dose is calculated as (Vd × target plasma concentration) ÷
bioavailability. A larger volume of distribution requires a higher loading dose.
Q8. A drug with a large volume of distribution (Vd) requires a higher loading dose
but may not be effectively removed by hemodialysis. Which pharmacokinetic
principle best explains this?
A. Extensive tissue binding limits extracorporeal removal
B. High renal clearance enhances dialysis removal
C. Low protein binding increases dialysis clearance
D. Large Vd indicates rapid hepatic elimination
Correct Answer: A
Rationale: A large Vd indicates extensive distribution into tissues, leaving little drug in
the vascular compartment accessible to dialysis. Only drugs with small Vd and low
protein binding are effectively removed by hemodialysis.
Q9. Which statement best describes the relationship between drug concentration
and response when a competitive antagonist is present?
A. The maximal efficacy of the agonist is reduced
B. The dose-response curve shifts to the right
C. The agonist becomes a partial agonist
D. The antagonist has no effect on potency
Correct Answer: B
Rationale: A competitive antagonist shifts the dose-response curve to the right,
GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS
SOLVED QUESTIONS & ANSWERS VERIFIED 100 %
Goodman and Gilman's The Pharmacological Basis of Therapeutics – Questions
with Detailed Rationales
SECTION 1: GENERAL PRINCIPLES OF PHARMACOLOGY (Q1–Q25)
Q1. Which statement best describes the historical role of medicinal plants in drug
discovery?
A. They primarily provided inactive placebo compounds
B. They served as direct sources of pharmacologically active molecules
C. They were used mainly to validate synthetic drug libraries
D. They contributed only to toxicology research
Correct Answer: B
Rationale: Goodman & Gilman describes medicinal plants as foundational sources of
bioactive compounds that directly led to the discovery of many therapeutic agents.
Morphine, quinine, and digoxin are examples of plant-derived drugs that remain
clinically essential.
Q2. What is the primary goal of lead compound optimization?
, Page 2 of 87
A. Eliminate all adverse effects
B. Improve potency, selectivity, and pharmacokinetic properties
C. Reduce molecular weight below a fixed threshold
D. Ensure complete receptor antagonism
Correct Answer: B
Rationale: Lead optimization focuses on enhancing efficacy, selectivity, and drug-like
properties while minimizing toxicity, as described in the drug discovery process.
Q3. A pharmaceutical team identifies a potent alkaloid from a medicinal plant that
inhibits a CNS enzyme but has poor oral bioavailability and high polar surface area.
Which lead-optimization strategy most directly addresses oral absorption and
brain exposure while preserving the core scaffold?
A. Introduce a permanently charged tertiary amine to increase water solubility
B. Mask polar groups as bioreversible esters (prodrug approach) to improve
permeability
C. Add multiple polar hydroxyl groups to enhance hydrogen bonding with plasma
proteins
D. Increase molecular weight by appending bulky aromatic rings to reduce clearance
Correct Answer: B
Rationale: Masking polar groups as bioreversible esters (a prodrug strategy) transiently
reduces polar surface area and increases membrane permeability for oral absorption
and CNS entry; esterase-mediated conversion regenerates the active scaffold.
Q4. High-throughput screening (HTS) is best described as:
A. Manual testing of compounds in animal models
B. Computational prediction of drug-receptor binding
C. Automated testing of large compound libraries against biological targets
D. Post-marketing surveillance of adverse drug reactions
, Page 3 of 87
Correct Answer: C
Rationale: HTS is defined as an automated method allowing rapid evaluation of
thousands of compounds for biological activity against specific targets.
Q5. Which term refers to a compound that shows desirable biological activity but
requires modification before clinical use?
A. Prodrug
B. Lead compound
C. Biomarker
D. Excipient
Correct Answer: B
Rationale: A lead compound is identified during screening as having promising activity
and serves as the starting point for further chemical refinement.
Q6. What is the primary determinant of a drug's ability to cross the blood-brain
barrier?
A. Molecular weight only
B. Lipophilicity and polar surface area
C. Plasma protein binding only
D. Route of administration only
Correct Answer: B
Rationale: The ability to cross the blood-brain barrier depends primarily on lipophilicity
(logP) and polar surface area (PSA). Drugs with high lipophilicity and low PSA penetrate
the CNS more readily.
Q7. Which pharmacokinetic parameter determines the loading dose required to
achieve a target plasma concentration?
, Page 4 of 87
A. Clearance
B. Volume of distribution (Vd)
C. Elimination half-life
D. Bioavailability only
Correct Answer: B
Rationale: The loading dose is calculated as (Vd × target plasma concentration) ÷
bioavailability. A larger volume of distribution requires a higher loading dose.
Q8. A drug with a large volume of distribution (Vd) requires a higher loading dose
but may not be effectively removed by hemodialysis. Which pharmacokinetic
principle best explains this?
A. Extensive tissue binding limits extracorporeal removal
B. High renal clearance enhances dialysis removal
C. Low protein binding increases dialysis clearance
D. Large Vd indicates rapid hepatic elimination
Correct Answer: A
Rationale: A large Vd indicates extensive distribution into tissues, leaving little drug in
the vascular compartment accessible to dialysis. Only drugs with small Vd and low
protein binding are effectively removed by hemodialysis.
Q9. Which statement best describes the relationship between drug concentration
and response when a competitive antagonist is present?
A. The maximal efficacy of the agonist is reduced
B. The dose-response curve shifts to the right
C. The agonist becomes a partial agonist
D. The antagonist has no effect on potency
Correct Answer: B
Rationale: A competitive antagonist shifts the dose-response curve to the right,
